Kornimate/medical-research-clean huggingface dataset:
left ventricular outflow tract mean velocity in children: a strong alternative to cardiac index in pediatric intensive care unit

Conditions: Shock Circulatory; Cardiogenic Shock

Summary: objectives: noninvasive assessment of cardiac index (ci) in pediatric critical ill patient is crucial. aortic velocity time integral (vti) valuable in adults, faces age and heart rate variability challenges in pediatrics, complicating ci interpretation in shocked patients. measurement errors can complicate ci evaluation, particularly in shocked patients. considering the proportional relationship between aortic annulus and body surface area (bsa) in children, along with the relatively constant mean aortic velocity, we studied if left ventricular outflow tract mean-velocity (lvotmv) reliably estimates bedside ci. design : retrospective, observational, single-center study. setting : pediatric intensive care unit (picu) in a tertiary care hospital. patients : one hundred forty-four children in picu (age 0-17 years, bsa 0.11-1.69 m2) requiring hemodynamic evaluation. intervention : bedside ultrasound by expert cardiologists measurements and main results : we explored the correlation between lvotmv (measured in pulse wave doppler from the apical five-chamber view) and standard ci estimation (multiplying aortic vti, heart rate, and aortic valve area). we excluded arrhythmia and anomalies of the left ventricular outflow tract.


Eligibility criteria:
inclusion criteria: * infants, children, and adolescents hospitalized in our pediatric intensive care unit (picu) in a non-surgical cardiology unit requiring hemodynamic assessment exclusion criteria: * documented irregular heart rates (hr) or with congenital heart malformations that could affect aortic measurements or lvot velocity (such as aortic valve anomalies)

Keywords: cardiac index hemodynamic echocardiography intensive care unit
effects of low-dose doxycycline on oral bone loss

Conditions: Periodontitis

Summary: the primary purpose of this clinical trial is to determine whether low-dose doxycycline can reduce alveolar bone density loss in postmenopausal osteopenic women with periodontitis and not on hormone replacement therapy (i.e., estrogen deficient).

the primary purpose of this clinical trial is to determine whether low-dose doxycycline (ldd) can reduce alveolar bone density loss in postmenopausal osteopenic women with periodontitis and not on hormone replacement therapy (i.e., estrogen deficient). the effects of ldd on alveolar bone height loss, progressive periodontal attachment loss, systemic bone mineral density, gingival crevicular fluid biochemical markers of collagen degradation and bone resorption and serum biomarkers of bone formation, bone resorption and inflammation also will be assessed. in addition, another objective is to determine if the microbial effects obtained with ldd over two years are equivalent to a placebo control. this clinical trial involves two clinical sites: the university of nebraska medical center college of dentistry and stony brook university school of dental medicine. a total of 128 postmenopausal osteopenic women with periodontitis between the ages of 45 and 70 at the time of telephone screening will be randomized to ldd or placebo groups and subjects will be followed for two years.

Eligibility criteria:
inclusion criteria: * subjects will be female, postmenopausal and not receiving estrogen replacement therapy. * subjects will be 45-70 years old at the time of telephone screening. * subjects will have osteopenia (t-score of -1.0 to -2.5) of the lumbar spine or femoral neck as determined by dual-energy absorptiometry (dexa) scans. * subjects will have a history of generalized moderate-advanced periodontitis and will be undergoing periodontal maintenance. * subjects will be in good general health and willing to sign the irb-approved consent form. exclusion criteria: * subjects will not have an allergy or hypersensitivity to tetracyclines. * subjects will not have diseases or take medications that affect the inflammatory or immune responses (e.g., chronic use of non-steroidal anti-inflammatory drugs) or bone remodeling (e.g., drugs such as prescription estrogens, bisphosphonates, calcitonin or steroids). * subjects will not have any medical condition requiring antibiotic premedication (e.g., prosthetic heart valves, prosthetic joints, and mitral valve prolapse with regurgitation) for routine dental therapy. * subjects cannot have diabetes mellitus. * subjects cannot have had active periodontal therapy (quadrant scaling and root planing or periodontal surgery) within the past year. * subjects cannot have osteoporosis (t-score greater than -2.5) of the lumbar spine or femoral neck.

Keywords: periodontitis, metabolic bone diseases, doxycycline
a study on vonoprazan in the real-world clinical practice in china

Conditions: Esophagitis Peptic

Summary: the purpose of this study is to evaluate the safety of vonoprazan by assessing all adverse events (aes), serious adverse events (saes), and adverse drug reactions (adrs) in routine clinical settings in china.

this is a prospective, non-interventional study in chinese participants with re who are receiving or will receive the standard treatment of vonoprazan. this study will assess the safety and effectiveness of vonoprazan in the real-world clinical practice. the study will enroll approximately 3000 participants. the data will be collected through participants' medical records, self-reported questionnaires, and recorded information on symptom via diaries. all the participants will be assigned to a single observational cohort: • participants with re the multi-center trial will be conducted in china. the standard treatment will be of 4 weeks or it may reach up to 8 weeks if the dosing proves insufficient. all participants will be followed up for additional 2 weeks after the standard treatment. the overall duration of the study will be approximately 10 weeks.

Eligibility criteria:
inclusion criteria: 1. must be undergoing treatment with vonoprazan. 2. must be at least 18 years old. 3. provide signed informed consent indicating that they (or a legally acceptable representative) have been informed of all pertinent aspects of the study and are willing to participate. exclusion criteria: 1. are currently enrolled in or plan to participate in any other clinical trials (that is interventional study). 2. are contraindicated for vonoprazan according to product package insert. 3. with a known hepatic function impairment, including jaundice.

Keywords: drug therapy
a study of pentamidine in the prevention of pneumocystis carinii pneumonia (pcp) in hiv-infected children who cannot take trimethoprim-sulfamethoxazole

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: primary: to compare the pharmacokinetics of biweekly and monthly dose regimens of intravenous pentamidine in hiv-infected infants and children who require pcp prophylaxis and who are intolerant to oral trimethoprim - sulfamethoxazole. to determine the safety and tolerance of these regimens in this patient population. secondary: to obtain information on the rate of pcp breakthrough in infants and children receiving parenteral pentamidine prophylaxis. prophylaxis against pneumocystis carinii pneumonia is recommended for all hiv-infected children considered to be at high risk. in children younger than 5 years of age with intolerance to trimethoprim - sulfamethoxazole, parenteral pentamidine may be a successful alternative.

prophylaxis against pneumocystis carinii pneumonia is recommended for all hiv-infected children considered to be at high risk. in children younger than 5 years of age with intolerance to trimethoprim - sulfamethoxazole, parenteral pentamidine may be a successful alternative. thirty-two children are randomized to one of two treatment arms. patients receive pentamidine on either a biweekly or a monthly treatment schedule. treatment continues until the last child enrolled has received at least 6 months of pentamidine. patients are stratified according to age \ = 24 months. steady-state pharmacokinetics will be examined in a subsample of 20 patients.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * steroids and intravenous immune globulin (ivig). patients must have: * documented hiv infection. * need for pcp prophylaxis. * known intolerance to trimethoprim - sulfamethoxazole (tmp-smx). one of the following required conditions: * known intolerance or allergy to dapsone; g6pd deficiency; history of serious or life-threatening reaction to tmp-smx; exclusion from protocol actg 179; election by parent not to enroll child on actg 179; or receiving medical care at sites not participating in actg 179. note: * co-enrollment in other actg pediatric studies is permitted. consent of parent or guardian is required. prior medication: allowed: * prior pentamidine. exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * active pcp. * pancreatitis defined as amylase elevation associated with an elevated lipase that is \> 2 x upper limit of normal. prior medication: excluded: * tmp-smx or dapsone within 7 days prior to study entry (toxicities to tmp-smx or dapsone must be clearly resolving).

Keywords: pneumonia, pneumocystis carinii pentamidine acquired immunodeficiency syndrome aids-related complex
biodistribution of [11c]pib in patients with risk factors for alzheimer's disease

Conditions: Alzheimer Disease; Mild Cognitive Impairment

Summary: participants enrolled at the alzheimer's disease research center (adrc) at wake forest school of medicine will be invited to take part in this study. the purpose of this study is to identify and measure the amount of a protein called amyloid in the brain.it is thought that the build up of amyloid may be related to the development of alzheimer's disease.

brain amyloid will be measured using pet with \[11c\]pib. participation will involve an initial brain scan and possibly a follow-up brain scan two years later. the data collected in this study will help explain amyloid deposits in several groups of participants including adults with and without signs of memory impairment. the information collected will help find out who is more likely to have brain amyloid and when it increases the risk for developing memory problems. research studies suggest that people with elevated levels of brain amyloid are at an increased risk for memory decline, but this does not mean that every person with amyloid build up will develop ad.

Eligibility criteria:
inclusion criteria: * enrolled in a study with the alzheimer's disease research center. exclusion criteria: -

Keywords: memory
treating cocaine abuse: a behavioral approach

Conditions: Cocaine Dependence

Summary: this study is designed to advance our development of a treatment for cocaine dependence. the investigators hypothesize that clients with high-risk characteristics will benefit from enhanced levels of treatment.

treatment development for cocaine dependence often proceeds without effort to adapt treatment parameters to patient characteristics. such a one-size-fits-all approach is problematic because of the heterogeneity of the clinical population. additionally, the approach is often subject to opposing biases either towards constraining costs or maximizing efficacy. this project includes two sequential clinical trails examining variations of the cra + vouchers treatment for cocaine dependence that are designed to explore matching treatment parameters to patient baseline characteristics known to moderate treatment response among cocaine-dependent outpatients. in trial 1, all patients were randomly assigned to receive 24 weeks of cra therapy but randomly assigned to one of three voucher-based incentive conditions: (a) 6 weeks of vouchers contingent on abstinence and incentive monetary value at usual level; (b) 6 weeks of vouchers contingent on abstinence but incentive value set at usual level for low-severity patients (intranasal cocaine users or married patients) and at twice the usual value for high severity patients (i.e., unmarried cocaine smokers/injectors), or to (c) a control condition where incentives were provided independent of recent cocaine use. in trial 2, all patients receive 12 weeks of abstinence-contingent incentives, but randomly assigned to also receive (a) 24 weeks of cra therapy or (b) 4 weeks of cra therapy. the overarching goal of the two trials is to strike a balance between the aforementioned biases towards constraining costs or maximizing efficacy and thereby facilitate cost containment without compromising efficacy, especially among more severe patients.

Eligibility criteria:
inclusion criteria: * 18 years and older * meets dsm iv criteria for cocaine dependence exclusion criteria: * psychosis * pregnancy * leaving immediate geographic area sooner than 6 months * an organic psychiatric disorder * medical illness such that participation is not feasible (e.g., on dialysis). * subjects in acute alcohol withdrawal * uncontrolled seizure disorder * significant depression or suicidal ideation (pending psychological evaluation)
fenoldopam in pediatric cardiac surgery

Conditions: Kidney Failure, Acute

Summary: the purpose of this study is to determine whether fenoldopam infusion during cardiopulmonary bypass in young children with congenital heart disease is able to reduce indicators of acute kidney injury (biomarkers reduction, diuresis increase) compared to a control group.


Eligibility criteria:
inclusion criteria: * children with congenital heart disease, less than one year old, undergoing surgery with the use of cardiopulmonary bypass exclusion criteria: * children over one year old, correction for ventricular or atrial septal defect, need for deep hypothermic circulatory arrest, preoperative renal dysfunction.

Keywords: cardiopulmonary bypass pediatric cardiac surgery acute renal failure renal biomarkers fenoldopam focus on optimization of perfusion during pediatric cpb
a study to compare two paracetamol formulations.

Conditions: Pain

Summary: a pharmacokinetic study investigating the rate and extent of absorption of paracetamol and an adjuvant from two different paracetamol formulations.


Eligibility criteria:
inclusion criteria: * healthy male or female volunteers aged 18-55 years with a body mass index ranging from 19-28 kilograms per square meter who have given informed consent

Keywords: healthy volunteer pharmacokinetics paracetamol
rotational narrow strip versus full conjunctival graft in pterygium excision

Conditions: Pterygium

Summary: to compare the efficacy of rotational narrow strip conjunctival graft to full conjunctival graft in primary pterygium excision. risk analysis of factors that may affects the recurrence rate.

pterygium is a raised, wing-shaped growth of fibrovascular tissue that extends horizontally from the bulbar conjunctiva, crossing the limbus, and onto the cornea. it is a common ocular surface disease in malaysia. pterygium can cause chronic ocular irritation, redness, tearing, visual impairment and poor cosmesis. treatment of symptomatic pterygium remains surgical. surgery should achieve low recurrence rate and acceptable cosmesis. various surgical techniques had been described with variable success. in this study, we compared the efficacy of rotational narrow strip conjunctival graft with the conventional full conjunctival graft in pterygium excision. patient will be follow up for a year after pterygium surgery. outcome will be recurrence rate between the two groups at one year. risk analysis of certain factors that affects the recurrence rate will be discussed.

Eligibility criteria:
inclusion criteria: 1. significant and symptomatic primary pterygium clinically requiring excision 2. willingness to participate in research project and to attend research time exclusion criteria: 1. age \< 21 years 2. glaucoma in the study eye 3. other concurrent ocular surface pathology 4. infection of the ocular surface 5. poor general health

Keywords: pterygium
crystalloids versus colloids during surgery

Conditions: Fluid Overload; Postoperative Complications

Summary: the purpose of the study is to test whether colloid-based goal-directed intraoperative fluid management leads to less perioperative morbidity compared to crystalloid-based goal-directed intraoperative fluid management. goal-directed therapy is based on measurements by an esophageal doppler device.

for a long time there is a raging debate whether crystalloid solutions or colloid solutions are better suited for fluid therapy. early proponents both for crystalloids \[shires 1961\] and colloids \[shoemaker 1979\] deserve credit for elucidating important facts about volume replacement therapy - without answering the primary question. elaborate reviews comparing crystalloid and colloid therapy for critically ill patients have been performed in the late nineties and updated recently \[roberts 2004\]. however, it has been suggested that both questions and answers of reviews leave us none but wiser \[webb 1999\]. although a plethora of studies comparing crystalloid vs. colloid therapy in the last decades have been published, volume replacement therapy is still considered to be based on dogma and personal beliefs \[boldt 2003\]. goal-directed intraoperative fluid therapy monitored by esophageal doppler identifies volume-responders, thereby decreasing length of stay in hospital in orthopedic \[sinclair 1997\], cardiac \[mythen 1995\], and abdominal surgery patients \[gan 2002, wakeling 2005, noblett 2006\]. however, all these studies have been performed with a colloid to be the substance applied. thus, it has been questioned whether monitoring with the esophageal doppler monitor, or the application of additional colloid improved outcome \[horowitz, kumar 2003\]. consequently, the researchers will use esophageal doppler monitoring for intraoperative goal-directed fluid therapy to compare the effects of crystalloid vs. colloid therapy on various organ systems, assessing combined perioperative morbidity \[bennett-guerrero 1999\] .

Eligibility criteria:
inclusion criteria: * after written informed consent patients undergoing elective open colon surgery, or open hysterectomy or myomectomy, or spine surgery or hip replacement will be included in the study. exclusion criteria: * patients having severe cardiac or renal insufficiency * patients with severe coronary artery disease * patients with insulin-dependent diabetes mellitus * patients with severe copd * patients with symptoms of infections or sepsis * patients with allergy to hydroxyethylstarch.

Keywords: intraoperative care ringer's lactate voluven cardiovascular diagnostic technique doppler effect
bi 207127 / faldaprevir combination therapy in hepatic impairment (child-pugh b) patients with genotype 1b chronic hepatitis c infection: hcverso3

Conditions: Hepatitis C, Chronic

Summary: to assess the pharmacokenetic characteristics of 600 mg bid bi 207127 / 120 mg qd faldaprevir /ribavirin in a small number of gt1b hcv infected patients with mild hepatic impairment (cpa) (arm 1) versus 400 mg bid bi 207127 / 120 mg qd faldaprevir /ribavirin in a small number of gt1b hcv infected patients with moderate hepatic impairment (cpb) (arm 2).


Eligibility criteria:
inclusion criteria: 1. treatment naïve and treatment experienced patients (prior relapse, interferon intolerant, and \[allowed in cohort a only\] prior partial response). 2. chronic hcv infection of genotype 1 (gt1), sub-gt1b virus only. 3. liver cirrhosis defined as metavir grade=4 or ishak grade =5 on liver biopsy or liver stiffness of =13 kpa on fibroscan. exclusion criteria: 1. hcv infection of mixed genotype (1/2, 1/3, and 1/4) or mixed sub-gt1a/1b or undefined diagnosed by genotypic testing at screening 2. liver disease due to causes other than chronic hcv infection which may include but is not limited to hemochromatosis, wilson's disease, or autoimmune liver diseases. 3. hiv infection 4. patients who have been previously treated with an investigational or approved daa
effects of hand massage applied with two different methods

Conditions: Angiopathy, Peripheral; Pain, Acute; Reflexology

Summary: there is no study finding examining the effects of the classical hand massage and hand reflexology massage methods on pain, anxiety and physiological parameters after coronary angiography. therefore, the aim of this study is to examine the effects of reflexology hand massage and classical hand massage on pain, anxiety and physiological parameters after coronary angiography.

there is no study finding examining the effects of the classical hand massage and hand reflexology massage methods on pain, anxiety and physiological parameters after coronary angiography.

Eligibility criteria:
inclusion criteria: * • patients who are over 18 years old * can speak turkish * agree to participate in the study * have not undergone emergency coronary angiography * have not consumed coffee or hypnotic drugs at least 12 hours before * have no history of chronic pain (e.g. arthritis) * are not addicted to alcohol or drugs * have no psychological problems (such as depression, anxiety disorder) * have no problem with having their hands massaged; those who do not have any skin lesions, sensory and motor disorders, amputations, burns, or pathological diseases related to muscles and bones * have not used anxiolytics exclusion criteria: * • those who do not volunteer to participate in the study * those who have any skin lesions, burns, open wounds, muscle and bone pathological diseases on their hands, * those who develop delirium during the follow-up period * those who develop complications after coronary angiography (such as bleeding, etc.) * arrhythmia * hemodynamic instability
seek, test, and retain. linkages for black hiv+, substance-using msm

Conditions: Substance Abuse; Sexual Behavior

Summary: the study will seek and recruit substance-using black men who have sex with men (msm) in new york city for human immunodeficiency virus (hiv) testing and will link and retain those who are hiv infected in hiv primary care. the star study has two primary objectives: to evaluate the feasibility and effectiveness of respondent driven sampling (rds) in the substance using black msm population for identifying individuals who are hiv infected and not in care; and to assess the relative effectiveness of patient navigation and financial incentives in linkage and retention to hiv care.

the hiv epidemic in the united states most severely affects men who have sex with men (msm): 61% of all new infections occur in this population. black msm bear a disproportionate burden, with prevalence of 28%, in contrast to 19% in msm overall. black msm undergo hiv testing less frequently than other msm; are less likely to be aware that they are hiv infected; are more likely to experience delays in entry into hiv care; and are less likely to be prescribed antiretroviral therapy (art) when eligible. these disparities are pronounced in substance-using msm, as substance users are at elevated risk of late diagnosis and delayed engagement in hiv care. the combination of pervasive stigma associated with msm behavior and high rates of substance use hinders effective prevention efforts in this population, even as the prevalence of infection in black msm in some us cities approaches 50%. reducing hiv-related disparities in msm and among black americans are national hiv/aids strategy priorities and are essential to the effort to control and prevent hiv/aids in the us.

Eligibility criteria:
inclusion criteria: * self-identify as black, african american, caribbean black, or multi-ethnic black * identify as male * greater than 18 years old * have had sex with a man during the preceding 12 months * have ever used illicit drugs or alcohol to intoxication exclusion criteria: \*participation in other study assessing linkage and retention in hiv care

Keywords: msm hiv substance abuse sexual behavior